Optimization of Protein Kinase CK2 Inhibitors Derived from 4,5,6,7-Tetrabromobenzimidazole
- 2 November 2004
- journal article
- research article
- Published by American Chemical Society (ACS) in Journal of Medicinal Chemistry
- Vol. 47 (25), 6239-6247
- https://doi.org/10.1021/jm049854a
Abstract
No abstract availableKeywords
This publication has 25 references indexed in Scilit:
- Protein kinase CKIIα interacts with the Bcr moiety of Bcr/Abl and mediates proliferation of Bcr/Abl-expressing cellsOncogene, 2003
- The specificities of protein kinase inhibitors: an updateBiochemical Journal, 2003
- One‐thousand‐and‐one substrates of protein kinase CK2?The FASEB Journal, 2003
- Inhibition of Protein Kinase CK2 by Anthraquinone-related Compounds: A STRUCTURAL INSIGHTPublished by Elsevier BV ,2003
- The Protein Kinase Complement of the Human GenomeScience, 2002
- Selectivity of 4,5,6,7‐tetrabromobenzotriazole, an ATP site‐directed inhibitor of protein kinase CK2 (‘casein kinase‐2’)FEBS Letters, 2001
- The Replacement of ATP by the Competitive Inhibitor Emodin Induces Conformational Modifications in the Catalytic Site of Protein Kinase CK2Journal of Biological Chemistry, 2000
- Protein Kinase CK2α′ Is Induced by Serum as a Delayed Early Gene and Cooperates with Ha-ras in Fibroblast TransformationPublished by Elsevier BV ,1998
- p53 deficiency and misexpression of protein kinase CK2α collaborate in the development of thymic lymphomas in miceOncogene, 1998
- Halogenated Benzimidazoles and Benzotriazoles as Selective Inhibitors of Protein Kinases CK-I and CK-II from Saccharomyces Cerevisiae and Other SourcesBiochemical and Biophysical Research Communications, 1995